Downloads
Protease-activated anti-Lewis Y antibody enhances selectivity and safety of glycan-targeting cancer therapy
Read MoreProtease-activated anti-Lewis Y antibody enhances selectivity and safety of glycan-targeting cancer therapy
PrecisemAb Biotech Unveils an Innovative Antibody Lock Mechanism to Overcome Anti-Idiotypic Antibody Interference in Long-Term Antibody Therapies
We are excited to announce our second publication of the year.The study titled “Spatial-hindrance-based pro-Adalimumab prevents…
PrecisemAb Publishes New Research on Tumor-Selective Activation Antibodies in the International Journal of Biological Macromolecules
We are pleased to share that our latest research article,“Development of a tumor-region-selective activation monoclonal antibody…
